MPLT – maplight therapeutics, inc. (US:NASDAQ)

News

Maplight Therapeutics (MPLT) is now covered by Needham & Company LLC. They set a "buy" rating and a $37.00 price target on the stock.
Maplight Therapeutics (MPLT) is now covered by TD Cowen. They set a "buy" rating on the stock.
MapLight Therapeutics, Inc. GAAP EPS of -$2.47 [Seeking Alpha]
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Maplight Therapeutics (MPLT) was downgraded by Wall Street Zen from "
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com